| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Viral and microbial enzymes involved in replication; immunomodulatory targets (immune system stimulation); anti-inflammatory pathways.
|
|---|---|
| ln Vitro |
In vitro, Dehydroandrographolide succinate exhibits antiviral activity by inhibiting microbial or viral enzymes. It shows immunostimulatory effects, enhancing host immune responses against viral infections. Anti-inflammatory activity is also observed in vitro, reducing inflammatory cytokine production. However, quantitative in vitro activity data (IC50 values) are not readily available in public literature.
|
| ln Vivo |
In vivo, Dehydroandrographolide succinate is used clinically for treating viral pneumonia and upper respiratory tract infections. Its immunostimulatory, anti-infective, and anti-inflammatory effects contribute to its therapeutic efficacy in respiratory viral infections. Detailed animal model efficacy data (e.g., in influenza-infected mice) is limited in publicly available sources.
|
| Enzyme Assay |
No specific cell-free enzyme assay protocol is detailed for Dehydroandrographolide succinate. As an antiviral compound targeting viral enzymes, typical cell-free assays would involve incubating the compound with purified viral polymerase or protease, measuring enzymatic activity via fluorogenic or radiometric substrates, and calculating IC50 values from inhibition curves.
|
| Cell Assay |
Cells (e.g., virus-infected epithelial cells, macrophages) are treated with serial dilutions of Dehydroandrographolide succinate. Antiviral activity is assessed by measuring viral titer reduction (plaque assay or qPCR) or cytopathic effect inhibition. Immunomodulatory effects are evaluated by measuring cytokine production (ELISA) and immune cell activation markers (flow cytometry) in treated versus untreated cells.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of viral infection (e.g., influenza virus-infected mice). Dehydroandrographolide succinate is administered via oral gavage or intraperitoneal injection. Endpoints include survival rate, lung viral titer, histopathological examination of lung tissue, and inflammatory cytokine levels in bronchoalveolar lavage fluid.
|
| ADME/Pharmacokinetics |
Molecular weight: 532.58; molecular formula: C28H36O10. Melting point: 136-138°C. Solubility: DMSO (187.8 mM). Storage: 2-8°C, protect from light. Density: 1.29 g/cm³. Boiling point: 733.8±60.0°C.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a semi-synthetic derivative of a natural product used clinically, it is considered to have a favorable safety profile, but standard toxicological studies (acute/chronic toxicity, genotoxicity, reproductive toxicity) would be required for full drug development.
|
| References |
|
| Additional Infomation |
Dehydroandrographolide succinate is a pharmaceutical compound used clinically in some regions (particularly in Asia) for the treatment of viral pneumonia and upper respiratory tract infections. It is not FDA-approved but is used in traditional and modern Chinese medicine. Its mechanism involves immunostimulation, anti-infection, and anti-inflammation. It acts as a prodrug of dehydroandrographolide, improving pharmacokinetic properties.
|
| Molecular Formula |
C28H36O10
|
|---|---|
| Molecular Weight |
532.5794
|
| Exact Mass |
532.23
|
| CAS # |
786593-06-4
|
| Related CAS # |
Kalii Dehydrographolidi Succinas;76958-99-1
|
| PubChem CID |
6540717
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
733.8±60.0 °C at 760 mmHg
|
| Melting Point |
136-138ºC
|
| Flash Point |
239.1±26.4 °C
|
| Vapour Pressure |
0.0±5.2 mmHg at 25°C
|
| Index of Refraction |
1.562
|
| LogP |
2.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
38
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2/C=C/C3=CCOC3=O)(C)COC(=O)CCC(=O)O)OC(=O)CCC(=O)O
|
| InChi Key |
YTHKMAIVPFVDNU-GPTWTFMPSA-N
|
| InChi Code |
InChI=1S/C28H36O10/c1-17-4-7-20-27(2,19(17)6-5-18-13-15-36-26(18)35)14-12-21(38-25(34)11-9-23(31)32)28(20,3)16-37-24(33)10-8-22(29)30/h5-6,13,19-21H,1,4,7-12,14-16H2,2-3H3,(H,29,30)(H,31,32)/b6-5+/t19-,20+,21-,27+,28+/m1/s1
|
| Chemical Name |
4-[[(1R,2R,4aR,5R,8aS)-2-(3-carboxypropanoyloxy)-1,4a-dimethyl-6-methylidene-5-[(E)-2-(5-oxo-2H-furan-4-yl)ethenyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~187.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8777 mL | 9.3883 mL | 18.7765 mL | |
| 5 mM | 0.3755 mL | 1.8777 mL | 3.7553 mL | |
| 10 mM | 0.1878 mL | 0.9388 mL | 1.8777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
